Quintrio
Home

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

Aligos Therapeutics, Inc. Common Stock

ALGS

Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.

Last trade $1.42
Day change -$0.24 (-14.46%)
Day range $1.40 – $1.69
Volume 35,787
Market cap $10M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$10.37M
Price / earnings
—
Price / book
0.92×
Price / sales
0.31×
EV / sales
-0.61×
EV / EBITDA
0.29×

Profitability

Earnings per share
-$10.61
Return on assets
-140.47%
Return on equity
-586.28%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0.01×
Current ratio
1.77×
Quick ratio
1.77×
Cash ratio
1.59×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$68.66M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for ALGS, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$2.87M$27.78M$2.83M$169K$741K$965K$311K$629K
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$2.87M$27.78M$2.83M$169K$741K$965K$311K$629K
Selling, general and administrative$5.87M$5.62M$6.41M$4.95M$5.17M$5.56M$5.05M$5.16M
Research and development$18.89M$24.05M$23.35M$17.04M$23.94M$13.98M$14.5M$16.03M
Total operating expenses$24.76M$29.67M$29.76M$21.98M$29.1M$19.53M$19.55M$21.19M
Operating income-$21.89M-$1.89M-$26.93M-$21.81M-$28.36M-$18.57M-$19.24M-$20.56M
Interest expense$169K$0$0$0$1.09M$0$0$0
Income before taxes-$21.53M$1.31M-$22.72M-$19.85M-$31.48M-$15.68M$43.13M-$82.12M
Income taxes$326K$2.81M$317K$30K$56K$185K$43K$27K
Net income-$21.86M-$1.5M-$23.04M-$19.88M-$31.54M-$15.86M$43.09M-$82.15M
Net income attributable to common shareholders-$21.86M-$1.5M-$23.04M-$19.88M-$31.54M-$15.86M$43.09M-$82.15M
EBITDA-$21.64M-$1.64M-$26.58M-$21.56M-$28.14M-$18.31M-$19.05M-$20.32M
Basic earnings per share-$2.09-$0.14-$2.21-$1.91-$3.04-$1.53$5.12-$13.08
Diluted earnings per share-$2.09-$0.14-$2.21-$1.97-$3.04-$1.53-$2.11-$13.09

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Aligos Therapeutics Presents Positive Data at the EASL Congress 2026

Aligos Therapeutics presented positive Phase 1 follow-up data for pevifoscorvir sodium showing sustained reductions in HBV viral markers and cccDNA reservoir. The company reported that 40% of HBeAg+ participants achieved HBsAg levels below 3,000 IU/mL at week 48, potentially qualifying them for functional cure therapy. Preclinical data demonstrated additive to synergistic effects when combining pevifoscorvir sodium with the ASO ALG-170675.

GlobeNewswire Inc.

Aligos Therapeutics Enters into Exclusive License Deal with Xiamen Amoytop Biotech Co., Ltd. to Develop and Commercialize Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection

Aligos Therapeutics has entered into an exclusive license agreement with Xiamen Amoytop Biotech to develop and commercialize pevifoscorvir sodium for chronic hepatitis B in Greater China. Aligos will receive a $25M upfront payment and up to $420M in milestone payments plus royalties, while retaining rights in the US, Europe, Japan, and South Korea. The deal extends Aligos' cash runway into Q4 2026.

GlobeNewswire Inc.

Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2025 Financial Results

Aligos Therapeutics reported significant progress in its Phase 2 B-SUPREME study of pevifoscorvir sodium for chronic hepatitis B, completing enrollment of HBeAg- participants with interim analyses expected in 2026. The company also advanced ALG-170675, a dual-mechanism antisense oligonucleotide, into IND-enabling studies in partnership with Xiamen Amoytop Biotech. ALG-055009 showed synergistic weight loss results when combined with incretin receptor agonists. Full year 2025 net loss improved to $24.2 million from $131.2 million in 2024, with cash and investments of $77.8 million expected to fund operations into Q3 2026.

GlobeNewswire Inc.

Aligos Therapeutics Presents Positive Data at the Conference on Retroviruses and Opportunistic Infections (CROI)

Aligos Therapeutics announced positive clinical data from two presentations at the Conference on Retroviruses and Opportunistic Infections (CROI) in Denver. The company presented Phase 1 monotherapy data for pevifoscorvir sodium, a potential first-/best-in-class CAM-E for chronic hepatitis B virus infection, showing high viral suppression. Additionally, Aligos presented pharmacokinetic data for ALG-097558, a pan-coronavirus protease inhibitor, in patients with renal and hepatic impairment.

GlobeNewswire Inc.

Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aligos Therapeutics announced that its Compensation Committee granted non-qualified stock options to purchase 81,100 shares to newly hired employees on January 29, 2026, as an inducement for employment. The options have an exercise price equal to the closing stock price on the grant date and will vest over four years with 25% vesting on the first anniversary.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Aug 19, 20241-for-25reverse split